The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Logiclinx Corporation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Logiclinx Corporation, a non-promoter entity based in the USA, has converted 42,96,956 warrants into equity shares of Telogica Limited via preferential allotment on 4th November 2025. After this conversion, Logiclinx holds 1,00,00,000 shares, representing 15.31% of the expanded share capital (15.06% on a diluted basis), up marginally from 15.06% diluted earlier. The actual number of shares held has not changed — only the nature shifted from warrants to equity. Telogica's total equity share capital rose from 5.71 crore to 6.53 crore shares due to this and likely other warrant conversions, meaning existing shareholders are being diluted.
Neutral to mildly negative for existing retail shareholders due to equity dilution, but reflects a pre-committed warrant conversion rather than fresh market buying, so no demand impact. The 15%+ stake by a non-promoter foreign entity signals meaningful institutional interest in the stock.